SEC Form 4 · accession 0001225208-19-003408
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth C Frazier
Officer — Chairman, President & CEO · Director
Period of report
Feb 21, 2019
Accepted (ET)
Feb 22, 2019 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2019 | M | 41,992 | $39.29 | A | 733,942 | D | |
| Common StockF2,F3 | Feb 21, 2019 | S | 41,992 | $80.0022 | D | 691,950 | D | |
| Common Stock | Feb 22, 2019 | M | 53,961 | $39.29 | A | 745,911 | D | |
| Common StockF4,F3 | Feb 22, 2019 | S | 53,961 | $80.0224 | D | 691,950 | D | |
| Common Stock - 401(k) PlanF5 | holding | — | — | — | 4,010 | I | By 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $39.29 | Feb 21, 2019 | M | 41,992 | D | May 2, 2013 | May 1, 2022 | Common Stock | 41,992 | 285,527 | D |
| Stock Option (right to buy)F6 | $39.29 | Feb 22, 2019 | M | 53,961 | D | May 2, 2013 | May 1, 2022 | Common Stock | 53,961 | 231,566 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F3Holdings include shares acquired in dividend reinvestment transactions.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F5Includes shares acquired and dividends earned through January 8, 2019, in the Merck U.S. Savings Plan, a 401(k) plan.
- F6The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.